Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Expression of VISTA on peripheral blood mononuclear cells in Systemic lupus erythematosus: association with disease activity and treatment status. | Clin Exp Med | 2026 | 42479216 | PubTator, text mining | PubMed |
| VISTA Deficiency Exacerbates Autoimmune Uveitis by Promoting Microglial Activation via the TLR4/MyD88/NF-κB Pathway. | Invest Ophthalmol Vis Sci | 2026 | 42479022 | PubTator, text mining | PubMed |
| Differential expression of immune checkpoint VISTA in inflammatory skin diseases. | J Invest Dermatol | 2026 | 42457021 | PubTator, text mining | PubMed |
| Single-Cell and Spatial Transcriptomics Reframe the Immunosuppressive Microenvironment of Neuroendocrine Neoplasms. | Cancers (Basel) | 2026 | 42449718 | PubTator, text mining | PubMed |
| High expression of VISTA on M-MDSCs is associated with immunosuppression and predicts poor prognosis in acute myeloid leukemia. | Sci Rep | 2026 | 42432069 | PubTator, text mining | PubMed |
| Revealing the dynamics of follicular T cells and checkpoint engagement in surgically resected colorectal cancer and their relations to clinicopathological aspects. | Clin Transl Oncol | 2026 | 42420747 | PubTator, text mining | PubMed |
| VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer. | Cancer Immunol Res | 2026 | 42390478 | PubTator, text mining | PubMed |
| PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression. | J Transl Med | 2026 | 42324467 | PubTator, text mining | PubMed |
| Targeting VISTA for immunomodulation in sepsis: mechanisms and therapeutic potentials. | Front Immunol | 2026 | 42292445 | PubTator, text mining | PubMed |
| Molecular Evaluation of RNA-Based Immune Checkpoint Profiling in Clear Cell Renal Cell Carcinoma. | J Clin Med | 2026 | 42279172 | PubTator, text mining | PubMed |
| Peptide occupancy governs HLA-E checkpoint interactions enabling VISTA recognition of destabilized HLA-E conformers. | Commun Biol | 2026 | 42243311 | PubTator, text mining | PubMed |
| The master regulators of delayed-type drug hypersensitivity reactions. | Curr Opin Allergy Clin Immunol | 2026 | 42234983 | PubTator, text mining | PubMed |
| Immune checkpoint inhibitors in medulloblastoma: current updates in preclinical and clinical developments. | Front Oncol | 2026 | 42180054 | PubTator, text mining | PubMed |
| VISTA as a Double-Edged immune checkpoint molecule in cancer and autoimmunity. | Adv Protein Chem Struct Biol | 2026 | 42177071 | PubTator, text mining | PubMed |
| A PET Radiotracer for Mapping VISTA in the Tumor Microenvironment. | Radiol Imaging Cancer | 2026 | 42171487 | PubTator, text mining | PubMed |
| T Cell Dysfunction in the Acidic Tumor Microenvironment. | Acta Physiol (Oxf) | 2026 | 42169514 | PubTator, text mining | PubMed |
| Combined targeting of VISTA and sorafenib activates T cell-mediated anti-tumor immunity via the NF-κB/TNF axis in hepatocellular carcinoma. | BMC Med | 2026 | 42106688 | PubTator, text mining | PubMed |
| VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma. | J Immunother Cancer | 2026 | 42103357 | PubTator, text mining | PubMed |
| LINC00632 combines with ERα to target VISTA expression, ameliorating endometriosis progression. | iScience | 2026 | 42088364 | PubTator, text mining | PubMed |
| Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: mechanisms, clinical trials, and therapeutic implications. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42059928 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=2